Up to 90% of Adults Carry a Silent 'Brain-Eating' Virus — And Researchers Just Found a New Way It Activates
Up to 90% of Adults Carry a Silent 'Brain-Eating' Virus — And Researchers Just Found a New Way It Activates
A virus that infects an estimated 50-90% of the human population lurks silently in cells for a lifetime — but when activated, it can destroy the brain. This week, researchers reported a newly discovered activation pathway that could affect up to 10% of adults worldwide.
The JC Virus
Human polyomavirus 2, commonly called the JC virus (or John Cunningham virus), was first isolated in 1971:
- Ubiquitous: Blood testing suggests 50-90% of adults have been exposed
- Silent infection: Initial infection is asymptomatic, typically occurring in childhood
- Transmission: Fecal-oral route; found in urine and stool of infected people
- Lifelong persistence: The virus establishes a permanent, dormant infection
When It Turns Deadly
For most carriers, the JC virus remains harmless forever. But for an unlucky few, it awakens and causes progressive multifocal leukoencephalopathy (PML):
- Mechanism: The virus reactivates, rearranges its genetic material, and invades the brain
- Target cells: Destroys oligodendrocytes — the cells forming myelin sheaths that protect nerve fibers
- Result: Extensive demyelination causing nerve dysfunction, disability, and death
- Historical context: PML gained attention as a complication of certain immunosuppressive drugs
The New Discovery
Researchers reported in Annals of Internal Medicine that there may be a new activation pathway:
- Broader population: This newly identified mechanism could affect up to 10% of adults
- Previously unknown: The pathway is distinct from the classic immunosuppression-triggered activation
- Diagnostic implications: May explain PML cases that occur in patients without obvious immune compromise
Who Is at Risk?
Traditional PML risk factors include:
- HIV/AIDS: PML was one of the defining AIDS-defining illnesses
- Immunosuppressive drugs: Natalizumab (multiple sclerosis), other monoclonal antibodies
- Organ transplant recipients: On chronic immunosuppression
- Chemotherapy patients: Particularly hematological cancers
The new research suggests risk may be broader than previously understood.
Why It Matters
The discovery has significant implications:
- Drug safety: Medications that suppress the immune system may carry unrecognized PML risks
- Screening: New understanding may lead to better screening for JC virus reactivation
- Treatment: Understanding activation pathways is crucial for developing PML treatments
- Public health: If 10% of adults carry a potentially activatable form, the public health impact is enormous
Current Treatment Landscape
PML remains devastating with limited treatment options:
- No cure: No antiviral drug specifically targets JC virus
- Immune reconstitution: Main treatment is restoring immune function
- High mortality: Historical mortality rates exceed 50%
Source: Ars Technica | Annals of Internal Medicine